LA MALATTIA DI ALZHEIMER
Alzheimer e genetica
I segni clinici
I primi sintomi
Quando rivolgersi al medico
Stadi della malattia
I problemi più frequenti
Come comportarsi con il malato
I disagi del familiare
Voce ai familiari
La posta del cervello
LA DIAGNOSI E LA CURA
Recently the EU Council of Ministers for Health underlined the importance of generating novel therapeutic agents both for symptomatic and disease modifying treatment of Alzheimer's disease (AD). However, despite the increased in translational medicine activities attrition rates still remain high and progress in bringing these biomarkers and models to a state of readiness as effective decision making tools is slow as each academic and pharmaceutical company work in isolation.
Bringing together European experts in technologies fully translatable from animal to human, experts in translational medicine, drug discovery and mathematical modelling, PHARMA-COG proposes to accelerate this validation using a 'MATRIX' approach i.e. conducting parallel experiments in animals and human using a comprehensive and standardised battery of behavioural, neurophysiological, morphological/functional imaging, and biochemical endpoints to:
The PHARMA-COG consortium consists of 30 public (Univeristies, Research Centres, Hospitals) and private partners (SMEs and EFPIA members), as well as a patients' Association Alzheimer Europe, coming from 10 different EU Members states. PHARMA-COG will also work closely with the EMEA, as an associated partner of this project, to share project progress and discuss the implications for drug development in Europe.. The combined size and expertise of PHARMA-COG provides a truly unique opportunity to validate the tools required to fundamentally change the drug discovery process in AD and accelarte efficacious drug to patients across Europe.
Workpackage 5 of PharmaCog (Identification of biomarkers sensitive to disease progression: Clinical Studies - European ADNI) is about the development of markers to track the progression of the disease in humans that are homologous to those used in animal models. WP5 uses as core markers those harmonized in the context of the North American ADNI and expands them with specific structural, functional, microstructural, molecular, central, and peripheral markers. WP5 is thus labeled as the "European ADNI".
The study plan to enrol 150 patients with mild cognitive impairment (MCI) according to the following inclusion criteria:
By the end of this 5-year project PHARMA-COG will have a) validated the tools necessary to streamline AD drug discovery and accelerate effective medicine to patients, b) set the standard for European drug discovery providing optimised and validated protocols c) provided the infrastructure to sustain world class drug discovery in Europe and d) disseminate the obtained results from health professionals to patients.